Physician profile
Ken Moadel
NPI 1407972326
$2,464.81
in general payments reported to CMS, 2019-2025
12 companies · $53.58 in 2025
The $53.58 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $244 · 2021: $1,371 · 2022: $255 · 2023: $239 · 2024: $201 · 2025: $53.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lensar, INC. | $1,124.56 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $742.94 | 2019-2024 | Idesign Rs, Tecnis Iol, Catalys System |
| Abbvie INC. | $134.50 | 2022-2025 | |
| Allergan, INC. | $118.21 | 2020-2022 | |
| Alcon Vision LLC | $91.19 | 2024-2025 | Wavelight Ex500 Excimer Laser, Clareon |
| Novartis Pharmaceuticals Corporation | $72.02 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $58.70 | 2023-2024 | Xiidra, Miebo |
| Sun Pharmaceutical Industries INC. | $28.46 | 2023 | Cequa |
| Rayner Intraocular Lenses Limited | $26.16 | 2024 | Omidria |
| Galderma Laboratories, L.P. | $23.68 | 2024 | |
| Eyevance Pharmaceuticals LLC | $22.77 | 2022 | |
| Csl Behring | $21.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ken Moadel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.